Head to head
Sophia Genetics vs Veeva Systems
Side-by-side on the measures that matter, with a plain-English read. Full detail: SOPH · VEEV
SOPH
Sophia Genetics
6.92-3.22%
1-year price shape — +72% over the period
Quant Rating B · 70/100
vs
VEEV
Veeva Systems
281.05-0.51%
1-year price shape — -8% over the period
Quant Rating D · 32/100
1-year performance, rebased to 100
Veeva Systems edges it on the scoreable measures. Veeva Systems earns the most per share.
| SOPH | VEEV | |
|---|---|---|
| Snapshot | ||
| Sector | Health Information Services | Health Information Services |
| Last price | 6.92 | 281.05 |
| Change today | -3.22% | -0.51% |
| 1-year return | +71.9% | -7.7% |
| Market cap | $589.08M | $45.50B |
| 52-week range | 3.75 – 8.98 | 148.05 – 302.17 |
| Valuation | ||
| P/E (TTM) | -5.97 | 46.07 |
| P/E percentile, own 5-yr range | 13th | 16th |
| P/B | 7.09 | 6.12 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -1.17 | 5.44 |
| Net profit (TTM) | $-99.60M | $880.78M |
| Revenue (TTM) | $86.17M | $3.46B |
| Revenue growth (YoY) | +27.2% | +17.6% |
| Gross margin | 66.6% | 75.0% |
| Operating margin | -85.5% | 29.9% |
| Net margin | -93.9% | 29.3% |
| Free cash flow (TTM) | $-50.46M | $1.67B |
| Ownership & sentiment | ||
| Institutional ownership | 62.0% | 91.0% |
| Insider activity (12mo) | 0 buy / 50 sell | 29 buy / 18 sell |
| Short interest (% of float) | 1.3% | 3.1% |
| Analyst consensus | 100% buy (4) | 73% buy / 23% hold / 5% sell (22) |
| Analyst price target | $12 (+66%) | $295 (+5%) |
| StockVane view | ||
| StockVane Quant Rating | B (70) | D (32) |
| Company | ||
| Employees | 415 | 7,928 |
| Founded | 2011 | 2007 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.